CRC CEO Tom Zoda Leads Key Discussion on CNS Clinical Trials at ASCP 2026#USA#Miami_Beach#Cognitive_Research#ASCP_2026#CNS_Trials
CRC CEO Tom Zoda Leads Key Discussion on CNS Clinical Trials at ASCP 2026
Tom Zoda, Ph.D., CEO of CRC, led a pivotal discussion at ASCP 2026 on reducing preventable failure risks in CNS clinical trials and enhancing study integrity.
third-news.com
June 3, 2026 at 12:48 PM
CRC CEO Tom Zoda Leads Key Discussion on CNS Clinical Trials at ASCP 2026#USA#Miami_Beach#Cognitive_Research#ASCP_2026#CNS_Trials
Sensorium Therapeutics to Unveil SNTX-2643 Data and Clinical Strategy at ASCP 2026#USA#Miami_Beach#Sensorium_Therapeutics#SNTX-2643#ASCP_2026
Sensorium Therapeutics to Unveil SNTX-2643 Data and Clinical Strategy at ASCP 2026
Learn about Sensorium Therapeutics' innovative SNTX-2643 for anxiety disorders, which will be showcased at the ASCP Annual Meeting 2026.
third-news.com
May 27, 2026 at 2:48 PM
Sensorium Therapeutics to Unveil SNTX-2643 Data and Clinical Strategy at ASCP 2026#USA#Miami_Beach#Sensorium_Therapeutics#SNTX-2643#ASCP_2026
Signant Health's Engagement at ASCP 2026 After Ametris Acquisition#United_States#Philadelphia#Signant_Health#Ametris#ASCP_2026
Signant Health's Engagement at ASCP 2026 After Ametris Acquisition
Signant Health will engage the CNS community at ASCP 2026, showcasing advancements post-acquisition of Ametris for improved clinical trials.
third-news.com
May 19, 2026 at 2:17 PM
Signant Health's Engagement at ASCP 2026 After Ametris Acquisition#United_States#Philadelphia#Signant_Health#Ametris#ASCP_2026